DataVXACS Applied Materials & InterfacesPaper
journal article·2026-06-10

A Covalently Engineered Metal–Organic Framework Nanosystem for Imaging-Guided Photoimmunotherapy of Metastatic Tumors

Jiangsheng Li, Wei Jin, Hongbo Wang, Shiyi Zhai, Benchao Zheng, Weiping Gao, Xunbin Wei, Kuangda Lu

ACS Applied Materials & Interfaces· Volume 18· Issue 22
Publisher page
Source abstract

Abstract

Metastatic cancer presents a formidable clinical challenge due to the limitations of conventional therapies in addressing both primary tumors and systemic spread. Here, we developed a supramolecular nanoscale metal-organic framework platform, UIO66-IR808-POEGMA (UIP), designed to integrate multimodal imaging with potent combination therapy for systemic intervention. UIP enables simultaneous photoacoustic and fluorescence imaging, providing real-time guidance for treatment. Upon 808 nm laser irradiation, the platform mediates synergistic photodynamic and photothermal effects, leading to the effective ablation of the primary tumors. Crucially, this localized therapy induces a robust antitumor immune response. In a murine model bearing 4T1 tumors, this imaging-guided strategy completely eradicated the primary tumors and markedly suppressed the growth of distant lesions (19.8% by volume compared to the PBS group). This work demonstrates UIP as a promising integrated theranostic system for imaging-guided control of metastatic disease.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Metal-Organic Frameworks: Synthesis and Applications · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Beijing Key Laboratory of Medical-Engineering Integration and Translation for Malignant Tumors and Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Institute of Advanced Clinical Medicine

Peking University

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)

Peking University Cancer Hospital & Institute

Institute of Medical Technology

Peking University Health Science Center

International Cancer Institute, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Clinical Medicine Plus X - Young Scholars Project, Peking University · Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases · Special Fund for Research on National Major Research Instruments of China · Regional Innovation and Development Joint Fund of National Natural Science Foundation of China

References (41)

Show source-provided references
1. 10.3322/caac.2165710.3322/caac.21657 ↗
2. 10.3322/caac.2011410.3322/caac.20114 ↗
3. 10.1016/j.nantod.2020.10100410.1016/j.nantod.2020.101004 ↗
4. 10.1039/C9CS00271E10.1039/C9CS00271E ↗
5. 10.1021/acsnano.9b0855010.1021/acsnano.9b08550 ↗
6. 10.1021/acs.accounts.0c0031310.1021/acs.accounts.0c00313 ↗
7. 10.1158/0008-5472.CAN-14-253810.1158/0008-5472.CAN-14-2538 ↗
8. 10.1038/s41587-022-01379-y10.1038/s41587-022-01379-y ↗
9. 10.1016/j.drudis.2019.11.00310.1016/j.drudis.2019.11.003 ↗
10. 10.1038/s41571-020-0413-z10.1038/s41571-020-0413-z ↗
11. 10.1038/s41571-021-00473-510.1038/s41571-021-00473-5 ↗
12. 10.1038/s41589-018-0161-x10.1038/s41589-018-0161-x ↗
13. 10.1038/srep1311010.1038/srep13110 ↗
14. 10.1021/acsami.0c0747110.1021/acsami.0c07471 ↗
15. 10.1038/s41551-018-0203-410.1038/s41551-018-0203-4 ↗
16. 10.1021/jacs.6b0666310.1021/jacs.6b06663 ↗
17. 10.1002/adma.20210256210.1002/adma.202102562 ↗
18. 10.1002/adma.20180224410.1002/adma.201802244 ↗
19. 10.1016/j.biomaterials.2016.01.00910.1016/j.biomaterials.2016.01.009 ↗
20. 10.1002/anie.20180513810.1002/anie.201805138 ↗
21. 10.1016/j.pdpdt.2024.10438710.1016/j.pdpdt.2024.104387 ↗
22. 10.1038/s44222-022-00017-110.1038/s44222-022-00017-1 ↗
23. 10.1038/s44222-024-00240-y10.1038/s44222-024-00240-y ↗
24. 10.1016/j.jcis.2023.12.08810.1016/j.jcis.2023.12.088 ↗
25. 10.1002/adfm.20160631410.1002/adfm.201606314 ↗
26. 10.1002/anie.20191142910.1002/anie.201911429 ↗
27. 10.1016/j.jcis.2023.12.12310.1016/j.jcis.2023.12.123 ↗
28. 10.1038/s41467-025-60572-010.1038/s41467-025-60572-0 ↗
29. 10.1002/adfm.20200243110.1002/adfm.202002431 ↗
30. 10.1021/jacs.8b0601310.1021/jacs.8b06013 ↗
31. 10.1002/cmdc.20160037410.1002/cmdc.201600374 ↗
32. 10.1021/acs.chemmater.8b0054610.1021/acs.chemmater.8b00546 ↗
33. 10.1016/j.jcis.2021.10.07010.1016/j.jcis.2021.10.070 ↗
34. 10.1021/jacs.2c1018810.1021/jacs.2c10188 ↗
35. 10.1021/acsnano.0c0451810.1021/acsnano.0c04518 ↗
36. 10.1038/s41467-022-30543-w10.1038/s41467-022-30543-w ↗
37. 10.1158/0008-5472.CAN-11-373310.1158/0008-5472.CAN-11-3733 ↗
38. 10.1038/nature0370310.1038/nature03703 ↗
39. 10.1038/s41577-021-00584-110.1038/s41577-021-00584-1 ↗
40. 10.1038/nm.420010.1038/nm.4200 ↗
41. 10.1021/jp064341w10.1021/jp064341w ↗